Clinical Studies Sponsored by SAGE Therapeutics | 24 results

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Name	NCT Number	Health Conditions in Trial	Clinical Trial Start Date	Study Completion Date	Clinical Trial Study Type
‌ Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression	NCT03924492	‌ Postpartum depression
‌ A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)	NCT04273191	‌ Postpartum Depression	2020	2021	Interventional
‌ A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)	NCT02942017	‌ Postpartum Depression	2016	October 11, 2017	Interventional
‌ A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting	NCT05059600	‌ Postpartum Depression	October 8, 2021	July 14, 2022	Interventional
‌ Evaluate SAGE-547 in Participants With Essential Tremor	NCT02277106	‌ Essential tremor	September 23, 2014	August 14, 2015	Interventional
‌ A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)	NCT03864614	Major depressive disorder	February 27, 2019	June 22, 2023	Interventional
‌ A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression	NCT02614547		December 15, 2015	June 22, 2016	Interventional
‌ Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression	NCT02285504	‌ Postpartum Depression	January 7, 2015	June 5, 2015	Interventional
‌ An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus	NCT02433314
‌ A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects	NCT03771586		September 24, 2018	January 2, 2019	Interventional
‌ A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects	NCT03844906		December 27, 2018	April 1, 2019	Interventional
‌ A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease	NCT05655520		December 14, 2022	2025	Interventional
‌ A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)	NCT02942004	‌ Postpartum Depression	August 1, 2016	October 19, 2017	Interventional
‌ A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)	NCT04537806	Acute respiratory distress syndrome COVID-19	December 18, 2020	July 1, 2021	Interventional
‌ Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants	NCT05049343		September 21, 2021	December 3, 2021	Interventional
‌ A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)	NCT03665038		September 7, 2018	January 8, 2021	Interventional
‌ Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus	NCT02052739		March 21, 2014	May 3, 2015	Interventional
‌ A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)	NCT04602624		February 2, 2021	September 21, 2021	Interventional
‌ A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects	NCT03770780		November 12, 2018	March 22, 2019	Interventional
‌ A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor	NCT05366751	‌ Essential tremor	June 13, 2022	2027	Interventional
‌ A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)	NCT04476017		July 31, 2020	March 25, 2022	Interventional
‌ A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B	NCT03787758		February 28, 2019	October 7, 2019	Interventional
‌ A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor	NCT04305275	‌ Essential tremor	June 15, 2020	February 15, 2021	Interventional
‌ A Study With SAGE-547 for Super-Refractory Status Epilepticus	NCT02477618		2015	August 11, 2017	Interventional